Biological treatment in multiple sclerosis. Review current development
Journal Title: Postępy Nauk Medycznych - Year 2013, Vol 26, Issue 10
Abstract
Multiple sclerosis (MS) is autoimmunological disorders of central nerves system (cns). Results of damage in cns cause by disease are serious deficits in different fields of human activities, also mental and in the end very heavy disability of people suffer from disease. We focus in treatment, especially in relapsing – remitting form of MS, on the protection of axon damage which causes progress of disease and disability, and finally life shortens in effect of disease. Currently we observe very rapid progress thanks of new discoveries of factors playing important role in mechanism of disease and development of pharmacology created new products able to modifying pathological activity of immunological system in cns. These medicines affect on different levels of pathological processes, within equal cns as well as besides it. This progress includes creation of new forceful medicines not only more effectivness, but it includes new, oral forms of medicines that makes considerable correction of comfort of treatment. Diversity of new medicine allows to employ principle of personation of treatment more forcefully. Additonally we can many times select and modify treatment depending on efficiency. Unfortunately we observed the major progress in the treatment of relapsing-remitting multiple sclerosis and in contrast we still have problems in treatment of primary progressive multiple sclerosis (PPMS). All clinical trials have failed and there is limited evidence of their efficacy in secondary progressive disease.
Authors and Affiliations
Witold Palasik
Keywords
Related Articles
- EP ID EP54584
- DOI -
- Views 116
- Downloads 0
Stimulation of iron-restricted erythropoiesis with iron (III) isomaltoside 1000 does not oversaturate transferrin in haemodialysed patients with anaemia – a retrospective study
Introduction. Iron deficiency, either absolute or relative, contributes to the developmentof anaemia in end-stage renal failure. Intravenous iron supplementation is a standardtreatment in patients on haemodialysis therap...
Diagnosis and treatment of non-Hodgkin lymphomas
Non-Hodgkin lymphomas are a group of malignancies characterized by a clonal expansion of lymphoid cells of B, T and natural killer cell lineages on various stages of their differentiation. Since lymphoid cells are morpho...
Rak wątrobowokomórkowy – rola leczenia chirurgicznego z uwzględnieniem zasad kwalifikacji do przeszczepiania wątroby
Rak wątrobowokomórkowy jest złośliwym nabłonkowym guzem stanowiącym około 80% wszystkich pierwotnych guzów wątroby. W epidemiologicznym rejestrze jest 5-tym co do częstości występującym nowotworem na świecie. W Polsce ob...
Assessment of platelet aggregation in clinical practice
Introduction. Platelet mediated thrombosis plays central role in pathogenesis of acute coronary syndromes (ACS). Employing the point-of-care (POC) VerifyNow assay allows for bedside monitoring of platelet aggregation in...
Nadciśnienie tętnicze u kobiet w ciąży
Nadciśnienie tętnicze (NT) w ciąży jest nadal mimo postępu medycyny istotną przyczyną chorobowości i umieralności matek, płodów i noworodków. Wikła 3-15% ciąż i w ok. 70% dotyczy pierworódek. W artykule przedstawiliśmy,...